+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating ASP1002 in adults with advanced or metastatic solid tumors that cannot be removed by surgery or have spread to other parts of the body. ASP1002 targets the Claudin 4 protein found on various tumors and is designed to activate the immune system to attack cancer cells. This early phase 1 study focuses primarily on assessing the safety, tolerability, and appropriate dosing of ASP1002 alone and combined with standard chemotherapies and immunotherapies in people previously treated or who have declined standard therapies. Participants will receive ASP1002 by intravenous infusion alone or together with standard chemotherapy drugs such as mFOLFOX6, FOLFIRI, TAS-102, pemetrexed, carboplatin, or docetaxel, and immunotherapies including bevacizumab, pembrolizumab, or ramucirumab. Treatment is given every 2 to 4 weeks in cycles lasting 21 or 28 days. The study has two parts Part 1 tests increasing doses of ASP1002 alone and with other treatments to find suitable doses, while Part 2 uses doses and combinations identified in Part 1 for further evaluation. During the study, participants will attend clinic visits for health checks, safety monitoring, and to report any medical issues. Every two months, scans such as CT or MRI will assess tumor response. Tumor samples will be collected before and during treatment, with optional samples after treatment ends. Follow-up visits will continue for up to one year after the last dose or until starting a new study treatment. Researchers will measure safety outcomes including side effects and laboratory results, as well as treatment effects on tumors and immune response.

Age: 18Years +All GendersPhase 1
15 locations
P

Actively Recruiting

Researchers are evaluating the drug PALI-2108 in adults with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. This phase 2 study compares different doses of PALI-2108 against a placebo to assess how well the drug works, its safety, and how the body processes it. The study focuses on measuring clinical remission and endoscopic improvement to understand the drugs impact. Participants will receive either 15 mg or 30 mg of PALI-2108 once daily or a matching placebo. The treatment is given orally, and the study uses a randomized, double-blind design where neither participants nor researchers know which treatment is assigned. The study includes induction and maintenance therapy periods, with assessments at 12 weeks and up to 48 weeks to evaluate clinical response and remission. During the study, participants will undergo regular clinical evaluations including the modified Mayo Score assessments, endoscopic examinations, and monitoring for adverse effects. The primary outcome is the proportion of participants achieving clinical remission at Week 12. Secondary outcomes include clinical response and endoscopic improvements at Weeks 12 and 48. Participants safety and drug effects will be closely monitored throughout the study duration, which may last up to about two years from enrollment.

Age: 18Years - 75YearsAll GendersPhase 2
115 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of the Change4Better C4B mobile app in reducing the severity of problem gambling compared to standard treatment as usual TAU. This study is a 6-month randomized clinical trial involving individuals with gambling disorder who are enrolled in or seeking treatment at outpatient facilities affiliated with Bettor Choice Gambling Treatment Programs or Kindbridge Behavioral Health. The study aims to assess the feasibility and efficacy of adding the C4B app, which is based on cognitive behavioral therapy, as a support tool alongside routine outpatient treatment. Participants will be randomly assigned to one of two groups one group will receive standard TAU, which includes individual or group therapy sessions tailored to their needs and usually lasts about one hour per week for 12 weeks. The other group will receive TAU plus access to the C4B mobile app, which teaches skills to manage gambling behaviors and cognitive distortions. Participants using the app will be instructed by staff on how to use it and encouraged to spend about 8 hours over 12 weeks completing modules and practicing exercises. Monthly follow-up continues for an additional 12 weeks, during which the app remains accessible. During the study, participants will be monitored for changes in gambling symptom severity from baseline to 6 months. Researchers will track app engagement through measures such as days used, topics completed, practice exercises, weekly usage, and total time spent. Participants will continue receiving usual outpatient care, and data will be collected through assessments and follow-ups conducted by the Yale research team. The total study duration for each participant is 6 months, starting from randomization.

Age: 18Years +All GendersPhase Not Applicable
6 locations
L

Actively Recruiting

Researchers are studying tulisokibart MK-7240, a medicine designed to treat active moderate to severe Crohns disease CD and ulcerative colitis UC. This is a Phase 3 extension study for people who previously received tulisokibart in earlier parent studies. The goal is to learn about the long-term safety and how well people tolerate tulisokibart over time. Participants in this study receive tulisokibart as a subcutaneous injection in different dose regimens, including low and high doses, some of which are blinded to the participant. The study compares these dosing regimens in parallel groups to monitor effects over a long period. During the study, participants will be monitored up to approximately 378 weeks to track any adverse events or reasons for stopping the study treatment. Researchers will collect safety data and assess tolerability while participants continue receiving the study drug. The total duration and follow-up extend for several years to understand long-term outcomes.

All AgesAll GendersPhase 3
37 locations
E

Actively Recruiting

Researchers are evaluating a medicine called survodutide in adults aged 18 and older who have confirmed non-alcoholic steatohepatitis NASH or metabolic-associated steatohepatitis MASH with cirrhosis, and a body mass index BMI of 27 kgm2 or higher, or 25 kgm2 for Asian participants. The study aims to find out if survodutide helps improve liver function and related health outcomes in these individuals. People with other chronic liver diseases or high alcohol intake are not eligible to participate. Participants are randomly assigned to one of two groups one group receives once-weekly injections of survodutide, and the other group receives a placebo injection that looks the same but contains no medicine. Both groups receive counseling to encourage dietary changes and regular exercise. The study is double-blinded, meaning neither participants nor doctors know which treatment is given. The trial lasts up to 4 and a half years, with visits either in person or via video calls scheduled every 2, 4, or 6 weeks for about 17 months, then every 3 months afterwards. Throughout the study, researchers monitor participants health, body weight, and any side effects. They use imaging methods to measure liver parameters and collect symptom questionnaires. The main outcome measured is the time until serious liver-related events occur, such as liver transplant or worsening liver function. Secondary outcomes include changes in liver fibrosis, body weight, blood sugar control, liver stiffness, and other health markers. This thorough monitoring helps compare the effects of survodutide to placebo over the long term.

Age: 18Years +All GendersPhase 3
447 locations
E

Actively Recruiting

Researchers are studying adults aged 18 and older who live with obesity and have a liver disease known as non-alcoholic steatohepatitis NASH or metabolic associated steatohepatitis MASH with moderate or advanced liver fibrosis. The study aims to evaluate whether a medicine called survodutide can improve liver function in people with these conditions. It is a Phase III, randomized, double-blind, placebo-controlled trial conducted at multiple centers. Participants are randomly assigned to one of two groups one receives weekly injections of survodutide, and the other receives placebo injections that look the same but contain no medicine. The survodutide dose is gradually increased until reaching the target dose. All participants receive counseling on diet and exercise. The study includes two parts the first focuses on the effect of survodutide on NASH and fibrosis over one year, and the second assesses its long-term safety and effectiveness over up to seven years. Participants stay in the study for up to seven years, attending regular visits either in person or remotely via video call. Visits occur every two weeks initially, then every four to six weeks, and later every three months. Doctors monitor health, record any side effects, and measure body weight and digestive symptoms. Liver assessments include imaging and biopsies at selected visits. Participants also complete questionnaires about symptoms and quality of life. Researchers compare results between the groups to assess the medicines effects on liver health and related outcomes.

Age: 18Years +All GendersPhase 3
532 locations
C

Actively Recruiting

Researchers are evaluating the best way to sample patients with known or suspected Barretts esophagus BE, a condition that increases the risk of developing esophageal adenocarcinoma, a type of esophagus cancer. The study compares the standard Seattle biopsy protocol, which takes tissue samples every 2 cm in four quadrants, to wide area transepithelial sampling WATS3D, which uses brushings to collect tissue. Detecting early precancerous changes called dysplasia is important to prevent cancer progression. Participants will undergo an upper endoscopy procedure where they will be randomly assigned to receive either the Seattle biopsy protocol or WATS3D sampling first, followed by the other technique during the same procedure. In cases where results differ between the two methods, a repeat endoscopy with Seattle biopsy sampling will be done to confirm findings. Both sampling methods are part of routine clinical care, and all biopsy samples will be analyzed by a central expert pathologist. Participants will be monitored for up to one year to measure how well each method detects dysplasia or intestinal metaplasia, with additional follow-up for up to five years to assess outcomes like progression to cancer and need for treatment. The study involves multiple centers and includes assessments such as endoscopic imaging, biopsy sampling, and pathology review. Approximately 2700 participants aged 18 to 89 years will take part, with visits occurring during the endoscopy and follow-up as needed.

Age: 18Years - 89YearsAll GendersPhase Not Applicable
14 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of VE303, a live biotherapeutic product, in preventing the recurrence of Clostridioides difficile infection CDI. This study focuses on participants with either recurrent CDI or primary CDI at high risk for recurrence, assessing the recurrence rate at 8 weeks after treatment. The study is a randomized, double-blind, placebo-controlled Phase 3 trial sponsored by Vedanta Biosciences, Inc. Participants receive either VE303 or a matching placebo after completing 10 to 21 days of standard antibiotic treatment for their CDI episode. Those assigned to the VE303 group take 3 capsules daily for 14 days the placebo group takes 3 placebo capsules daily for the same duration. The capsules look identical to ensure blinding. This treatment period follows the completion of their initial antibiotic therapy. Throughout the study, participants are monitored for CDI recurrence up to 8 weeks after treatment. Researchers evaluate safety and measure the rate of CDI coming back during this period. Participants must have completed standard antibiotic therapy and meet clinical stability criteria before starting the study drug. The total participation time includes screening, treatment, and observation phases until the primary outcome at week 8 is assessed.

Age: 12Years +All GendersPhase 3
215 locations